(RTTNews) - Coya Therapeutics, Inc. (COYA) announced the appointment of Fred Grossman to its senior management team as President and Chief Medical Officer. Grossman will succeed Adrian Hepner, effective July 17, 2023. Prior to joining Coya, Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He also served as President and Chief Medical Officer at Glenmark Pharmaceuticals, based in India. Coya Therapeutics said Grossman will guide and oversee all of Coya's development programs, including 
its lead asset, COYA 302, for the treatment of Amyotrophic Lateral Sclerosis. For More Such Health News, visit rttnews.com.  Indices Commodities Currencies Stocks